| Description | CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. |
| In vitro | CB-103在人类T细胞急性淋巴细胞性白血病（T-ALL）癌细胞系中显示出阻断NOTCH信号传递的能力，并且在对GSI抗性的T-ALL细胞系中表现出抗肿瘤效果[2]。 |
| In vivo | CB-103在三阴性乳腺癌中抑制GSI/Mab耐药细胞的生长，并在人类T-ALL和小鼠乳腺肿瘤异种移植模型中展现出抗肿瘤活性[3]。 |
| molecular weight | 242.32 |
| Molecular formula | C15H18N2O |
| CAS | 218457-67-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (206.34 mM), Sonication is recommended. |
| References | 1. Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2. 2. R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway. 3. Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway. |